Small-Cap Momentum Watch: Upcoming Catalysts for November 9–13
11/9/202613 min read
From operational updates to conference participation, we’ve highlighted the small-cap events that could drive attention this week.
--
Companies Participating at BIO-Europe 2026
BIO-Europe 2026 will take place November 9–11, 2026, at Koelnmesse in Cologne, Germany. Organized by Informa Connect, the annual event brings together biotechnology and pharmaceutical companies, institutional investors, industry executives, and business development professionals for strategic partnering meetings, company presentations, panel discussions, and networking opportunities. The conference will feature expanded strategic content tracks, plenary sessions, and one-on-one meetings through the partneringONE platform, focusing on clinical development, licensing opportunities, regulatory advancements, manufacturing innovation, and strategic collaborations across the global biopharmaceutical industry.
CANF, GRCE, MDCX, AZTR, ARTL, AVXL
Companies Participating at the Guggenheim 3rd Annual Healthcare Innovation Conference 2026
The Guggenheim 3rd Annual Healthcare Innovation Conference will take place November 9–11, 2026, in Boston, Massachusetts. Hosted by Guggenheim Securities, the annual event brings together biotechnology and healthcare companies, institutional investors, industry executives, and healthcare professionals for company presentations, fireside chats, one-on-one investor meetings, and discussions focused on innovative therapies, clinical development programs, emerging medical technologies, and growth opportunities across the healthcare sector. Participating companies will have opportunities to highlight clinical trial progress, upcoming regulatory milestones, pipeline developments, and strategic initiatives, with select presentations available through live and archived webcasts.
EYPT, RNTX, ANTX, APRE, PMN, CRBP, OVID, LSTA, EDSA, IMRX, LRMR, UNCY, XFOR, ZNTL, IRD, RFL, ADCT, CCCC, FHTX, CABA, CALC, IBIO, SPRO, CMPX, RZLT, CTMX, SION, PYXS
Companies Participating at the Society for Neuro-Oncology 31st Annual Meeting & Education Day 2026
The Society for Neuro-Oncology (SNO) 31st Annual Meeting & Education Day will take place November 12–15, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The annual event brings together more than 3,000 neuro-oncology researchers, clinicians, biotechnology companies, and industry professionals from around the world to share advances in brain and central nervous system (CNS) cancer research and treatment. Under the theme "Crossing the Translational Divide: From Neurons to Novel Therapies," the conference will feature scientific presentations, clinical research updates, educational sessions, and discussions focused on emerging therapies, diagnostic innovations, and multidisciplinary approaches to treating CNS malignancies.
NTHI, NUVB, CNSY, BLRX, RADX
Companies Participating at the Stifel 2026 Healthcare Conference
The Stifel 2026 Healthcare Conference will take place November 10–12, 2026, at the Lotte New York Palace Hotel in New York City. Hosted by Stifel, the annual event brings together biotechnology, pharmaceutical, medical technology, and healthcare companies, institutional investors, industry executives, and financial professionals for company presentations, fireside chats, one-on-one investor meetings, and discussions focused on clinical development, regulatory milestones, emerging medical technologies, commercialization strategies, and growth opportunities across the healthcare sector. Participating companies will have opportunities to highlight pipeline developments, upcoming clinical catalysts, financial performance, and strategic initiatives, with select presentations available through live and archived webcasts.
MGNX, OKYO, PMN, EYPT, OVID, DARE, VNDA, XFOR, TMCI, ZNTL, CGEN, GERN, FHTX, CMPX, SION, LUNG, PYXS, MXCT, OM, OABI, IPHA, ANTX, CLLS
Companies Participating at the Canaccord Genuity 2026 MedTech, Diagnostics & Digital Health Forum
The Canaccord Genuity 2026 MedTech, Diagnostics & Digital Health & Services Forum will take place on November 11, 2026, in New York City. Hosted by Canaccord Genuity, the one-day event brings together public and private medical technology, diagnostics, digital health, and healthcare services companies, institutional investors, industry executives, and healthcare professionals for company presentations, fireside chats, one-on-one investor meetings, and discussions focused on emerging medical technologies, diagnostic innovations, digital healthcare solutions, commercialization strategies, and growth opportunities across the healthcare sector.
QTI, KRMD, LUCD, PAVM, CVRX, TLSI, LUNG, RNXT, MDXG
Companies with Material Events This Week:
GRCE – CEO Prashant Kohli will participate in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany. Management will meet with biotechnology industry representatives, investors, and potential strategic partners to discuss the company's GTx-104 program, an investigational intravenous formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, and potential business development opportunities.
ALT – Will present late-breaking Phase 2 RECLAIM clinical trial results for pemvidutide in adults with moderate-to-severe alcohol use disorder at the AASLD Liver Meeting 2026 in Denver, Colorado. The oral presentation is scheduled for November 9 at 10:30 a.m. MT and will highlight 24-week efficacy and safety findings, including reductions in heavy drinking days, improvements in WHO risk drinking levels, and achievement of alcohol abstinence-related endpoints compared with placebo.
LXEO – Will present four studies involving its LX2006 gene therapy program at the International Congress for Ataxia Research (ICAR), November 10–13, in Atlanta, Georgia. An oral presentation on November 11 at 3:06 p.m. ET will highlight safety and preliminary efficacy findings in Friedreich ataxia cardiomyopathy. Additional posters on November 11–12 will cover neurological disease progression, cerebellar gene delivery, immune responses, and patient perspectives on cardiac complications associated with Friedreich ataxia.
ALLO – Will release updated clinical and translational data from its RESOLUTION study evaluating ALLO-329 at the American College of Rheumatology Convergence 2026 on November 9. The expanded dataset will include additional patients, longer follow-up, and findings across three dose levels and three lymphodepletion approaches, with particular focus on systemic sclerosis. Management will host a webinar at 9:00 a.m. ET to review emerging safety, efficacy, and conditioning-related findings ahead of the scientific poster presentation later that day.
PACB – Management will participate in the UBS Global Healthcare Conference on November 9, 2026, in Palm Beach Gardens, Florida. A fireside chat is scheduled for 5:00 p.m. ET, providing an opportunity to discuss the company's sequencing technologies, commercial performance, and business strategy.
CLOV – Interim Chief Financial Officer Clay Thornton will present at the UBS Global Healthcare Conference on November 9, 2026, at 12:30 p.m. ET. The presentation will provide an opportunity to discuss Clover Health's Medicare Advantage business, financial performance, technology initiatives, and growth strategy.
DNUT – Will participate in the Restaurant Finance & Development Conference, November 9–11, in Las Vegas, Nevada. CEO Josh Charlesworth and CFO Raphael Duvivier will attend, with Charlesworth participating in a conference panel. Ahead of the event, Krispy Kreme will unveil its first Hot Light Express test location at the Excalibur Hotel & Casino, introducing a smaller-footprint shop concept designed to expand access to fresh, hot doughnuts. The company remains in the initial testing phase, with no systemwide rollout currently planned.
MMA – Will begin its next TrainAlta Warrior Training Program cycle across 27 UFC GYM locations on November 9, 2026. The expanded rollout, which is expected to be the largest launch in the partnership's history, follows the opening of pre-sales and represents continued growth of the company's fitness training operations through its UFC GYM partnership.
ACRV – Will host a webcast with key opinion leaders on November 10, 2026, at 4:00 p.m. ET to discuss its newly acquired ACR-525 program, a Phase 2-ready oral selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program acquired from Aqilion AB. Management will review the programs' potential in autoimmune and inflammatory diseases, including eosinophilic esophagitis, and discuss how its AI-driven AP3 phosphoproteomics platform could support patient selection, biomarker development, and future clinical studies.
TWI – Management will participate in Baird's 2026 Global Industrial Conference on November 10, 2026, at The Ritz-Carlton in Chicago. The event provides an opportunity to discuss the company's off-highway tire and wheel operations, financial performance, industrial market conditions, and strategic growth initiatives.
STKE – CFO Doug Harris and Head of Capital Markets Stephen Ehrlich will participate in Cantor's 4th Annual Crypto, Fintech, AI & Energy Infrastructure Conference, November 10–12, at The Ritz-Carlton in Miami Beach, Florida. Management will be available for investor meetings and discussions concerning the company's business strategy and initiatives.
FOCL – Management will participate in the UBS Global Healthcare Conference on November 10, 2026, with a fireside chat scheduled for 1:15 p.m. ET. The company will discuss its robotic focal therapy business and growth opportunities, with live and archived webcasts available to investors.
SRTA – Management will present at the UBS Global Healthcare Conference on November 10, 2026, at 12:30 p.m. ET, providing an opportunity to discuss corporate developments, operating performance, and strategic priorities with institutional investors.
INO – Will present its INO-D001 program for hemophilia A at the World Federation of Hemophilia New Technology & Gene Therapy Workshop on November 12, 2026, in Montreal, Canada. The presentation will focus on the company's investigational gene therapy approach for treating hemophilia A.
BGDE – Executive Chairman Josh Kilgore and CEO Phil Stanley will participate in the Cantor Crypto and AI Infrastructure Conference, November 10–12, in Miami, Florida. Kilgore will join a panel discussion on November 12 at 11:20 a.m. ET, while management will meet investors to discuss the company's digital infrastructure business and development strategy.
EDBL – CEO Jim Kras will participate in the 2026 CEAg World Conference & Expo, November 10–11, in Charlotte-Concord, North Carolina. On November 10, he will join the "Diversification Beyond Core CEA" session to discuss the company's expansion beyond controlled environment agriculture into value-added foods, clean-label nutrition, and ready-to-drink beverages, supported by proprietary technologies, retail relationships, and strategic partnerships.
LINK – Will showcase its sensor technologies and printed electronics solutions at Electronica 2026, November 10–13, in Munich, Germany. The company will exhibit its sensor portfolio and custom solutions at Booth B4 223, with Vice President Declan Flannery delivering a presentation on November 12 at 1:40 p.m. on the Smart Mobility Stage. Management will also participate in Medica in Düsseldorf, highlighting medical-grade sensing technologies and wearable healthcare applications.
IMMP – Will present late-breaking Phase 1 clinical trial findings for IMP761 at the American College of Rheumatology Convergence 2026 on November 10 from 10:30 a.m.–12:30 p.m. ET in Orlando, Florida. The poster will highlight findings from the randomized, placebo-controlled first-in-human trial of the company's immunosuppressive LAG-3 agonist antibody in healthy volunteers, evaluating its potential as a novel treatment approach for autoimmune diseases.
IVDA – Will conduct a live flight demonstration of its GX11 IvedaAir unmanned helicopter on November 10, 2026, in Mesa, Arizona. The invitation-only event, co-hosted with GlobalMed, will showcase autonomous flight, cargo delivery, and real-time aerial video analysis through IvedaAI. Government agencies, defense contractors, and prospective customers will observe the platform's capabilities, including a maximum 26-pound payload, extended flight endurance, and applications in public safety, emergency response, defense, and critical infrastructure.
AUTL – Will present updated Phase 1 CARLYSLE clinical trial data evaluating obecabtagene autoleucel (obe-cel), its CD19-directed CAR-T therapy, in adults and adolescents with severe refractory systemic lupus erythematosus at ACR Convergence 2026. The poster presentation is scheduled for November 10 from 10:30 a.m.–12:30 p.m. ET and will include updated safety and efficacy findings with up to 20 months of follow-up in adults and at least three months of follow-up in adolescent patients.
ELTX – Will host a virtual key opinion leader event on November 11, 2026, at 2:30 p.m. ET featuring oncologists from Memorial Sloan Kettering Cancer Center. The discussion will focus on camupepimut (ELI-002 7P), the company's investigational KRAS-targeted immunotherapy, including Phase 2 clinical findings, the treatment landscape for metastatic pancreatic cancer, and opportunities to expand development into neoadjuvant treatment through an ongoing Phase 1 clinical trial.
LOT – CFO Dr. Daxue Wang and Head of Capital Market Michelle Ma will present at Deutsche Bank's American Depositary Receipt Virtual Investor Conference on November 12, 2026, at 8:00 a.m. ET. The event will provide international investors with an opportunity to review the company's luxury mobility business, financial developments, and strategic priorities.
LRMR – Will present three posters at the International Congress for Ataxia Research 2026, November 10–13, in Atlanta, Georgia. All presentations are scheduled for November 12 from 6:30–7:30 p.m. ET and will highlight previously disclosed interim clinical findings from its ongoing open-label nomlabofusp study in Friedreich ataxia, along with new plasma lipid and gene expression analyses evaluating biological changes associated with treatment.
BRIA – CEO Kendrew Hartanto will participate in the A.G.P. Virtual Consumer Showcase on November 12, 2026, with a fireside chat scheduled for 9:45–10:15 a.m. ET. Management will discuss the company's intimate apparel business, corporate developments, and growth opportunities with existing and prospective investors.
MOB – Will participate in UVID DroneTech 2026 on November 12 in Tel Aviv, Israel, introducing its newly launched SwarmiX family of secure mesh communication solutions to the Israeli defense market. The company will conduct a live demonstration using unmanned aerial and ground platforms, while General Manager Udi Altshuler will speak about the growing operational requirements for coordinated drone fleets, manned-unmanned teaming, and counter-UAS systems.
AQST – Will present multiple clinical and research studies at the American College of Allergy, Asthma, and Immunology Annual Meeting, November 12–16, in Phoenix, Arizona. Two oral presentations scheduled for November 14 will highlight pharmacokinetic and pharmacodynamic findings for Anaphylm (dibutepinephrine) sublingual film, including evaluations in patients with and without allergic reaction symptoms and the effects of top-of-tongue administration. Additional presentations will address healthcare provider perspectives on epinephrine delivery for anaphylaxis.
BODI – Is scheduled to launch INSANITY: Unhinged, the next installment in its INSANITY fitness program franchise, exclusively through BODi Fitness on November 12, 2026. The upcoming release follows the company's introduction of a limited-edition Cinnamon Roll Whey Shakeology flavor with zero grams of added sugar, expanding its digital fitness and nutrition offerings.
WSHP – CEO Maria Weaver will present at the A.G.P. Virtual Consumer Showcase on November 12, 2026, at 10:30 a.m. ET. The presentation will review WeShop's community-owned shopping platform, lessons from its U.K. pilot program, the roadmap for its U.S. launch, and plans to expand commerce, advertising, and retail media revenue.
INBS – Vice President of Global Sales Doug Heath will present at the Webull Biotech Webinar on November 12, 2026, at 2:00 p.m. ET. The virtual presentation will highlight the company's noninvasive diagnostic testing technologies and business developments, followed by a live investor question-and-answer session.
NERV – Will host an in-person and virtual key opinion leader event in New York City on November 12, 2026, at 10:00 a.m. ET focused on roluperidone for the treatment of negative symptoms of schizophrenia. Medical experts will discuss new analyses supporting the drug's efficacy and safety, the current treatment landscape, and an update on the company's ongoing Phase 3 clinical trial, followed by a live Q&A session.
PRZO – Will showcase its newly launched TillOnAIR autonomous counter-drone defense system at UVID DroneTech 2026 on November 12 in Tel Aviv, Israel. The system combines ground-based detection and guidance with reusable drone interceptors and net-based interception technology. The company also plans a series of demonstrations during November for government, military, defense, and security organizations to highlight autonomous perimeter protection, electronic interference resilience, and multi-threat interception capabilities.
EVLV – Management will participate in the BMO Technology Conference on November 12, 2026, in New York City. The event will provide an opportunity to discuss the company's AI-powered security screening technologies, commercial developments, and business growth strategy with institutional investors.
GPUS – Will host a virtual Investor Day on November 12, 2026, from 1:15–3:30 p.m. PT to discuss progress at its Michigan AI data center campus and potential strategic alternatives. Management will provide updates on its agreement for an initial 20 MW AI compute deployment, with options for an additional 32 MW that could potentially generate more than $3 billion in cumulative contract revenue over 20 years if fully exercised. The company will also discuss possible alternatives involving the sale of the Michigan campus, a potential Sentinum IPO, and strategic transactions involving its askROI AI software subsidiary.
GANX – Will present two late-breaking research posters at the 31st IAPRD World Congress on Parkinson's Disease and Related Disorders, November 11–14, in Milan, Italy. A guided poster presentation scheduled for November 13 from 3:30–4:30 p.m. CET will highlight open-label extension findings from its Phase 1b rexaceract (GT-02287) study in Parkinson's disease. An additional poster will cover preclinical development of GT-04686, a GCase allosteric modulator being studied in a GBA1 Parkinson's disease model.
DLNG – November 13, 2026, is the record date for its declared quarterly cash distribution of $0.05 per common unit for the quarter ended September 30, 2026. The distribution is scheduled to be paid on or about November 20 to eligible common unitholders.
BIVI – Will deliver a late-breaking oral presentation at the 4th Long COVID International Conference, November 12–13, in Nice, France. The presentation is scheduled for November 13 at 3:30 p.m. and will highlight additional findings from its randomized Phase 2 ADDRESS-LC trial of bezisterim, including improvements in fatigue, post-exertional malaise, and cognition among prespecified high-symptom-burden subgroups. The presentation will also feature previously undisclosed biomarker data.
MDAI – Will participate in the Northeast Region Burn Conference, November 13–14, 2026, in Boston, Massachusetts. The event will feature a key opinion leader presentation by Dr. Alisa Savetamal of the Connecticut Burn Center examining how artificial intelligence evaluation of multispectral imaging can improve physician accuracy in identifying non-healing burn wounds.
GVH – Will host the 2026 OK TAECYEON FANMEETING IN MACAU “TodaY” on November 14, 2026, at The Grand Hall, Grand Lisboa Palace Resort Macau, through its subsidiary Loomi Entertainment Group. The event marks K-pop star OK TAECYEON's first solo fan meeting in Macau and Globavend's first organizer-led live entertainment event outside Hong Kong. The expansion follows the company's participation in the sold-out MAMAMOO 2026 World Tour concert in Hong Kong and supports its strategy to expand into concerts, fan meetings, and other live entertainment experiences.
EU – Expects final Texas Commission on Environmental Quality authorization for its Upper Spring Creek PAA-1 uranium production area on or before November 13, 2026. The satellite ion-exchange plant and initial production wellfield are constructed, with uranium extraction expected to begin shortly after authorization, subject to final operational approval of the waste-disposal well. At Alta Mesa, the PAA-3 Extension remains targeted for approval by year-end 2026, while PAA-8 is expected in early 2027.
ENVX – November 13, 2026, is the record date for Enovix's special warrant dividend. Eligible shareholders will receive one warrant for every four common shares held, with an initial exercise price of $3.00 per share. November 12 is the final expected purchase date for dividend eligibility. Warrant distribution is scheduled for November 18, with separate Nasdaq trading under ENVXW anticipated to begin November 19, subject to applicable approvals.
PDC – The 30-day advance-notice period associated with Perpetuals' proposed Tokenized Securities Venue is expected to conclude around November 13, 2026, following its October 14 notice submission confirmed on the SEC's official Innovation Exemption list. The company intends to introduce tokenized U.S. equity trading through its digital asset infrastructure. Commencement of operations remains conditional on meeting applicable SEC exemption requirements, and no firm launch date has been announced.
GENK – Is working toward completion of its proposed $100 million transaction with Chubby Group involving 47 U.S. restaurants. The October 14 binding letter of intent originally targeted closing within 30 days, placing the estimated milestone around November 13, 2026, subject to definitive agreements, required approvals, and transaction conditions. The proposed transaction would substantially reduce restaurant lease obligations while GEN retains its brand and consumer packaged goods business.
--
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.
Disclaimer: Penny stock trading involves substantial risk, so always research every alert before trading, consult with a licensed professional before trading, only invest what you can afford to lose, and always trade with caution. Readers should independently investigate and fully understand all risks before investing. Results listed are NOT typical and individual results may and most likely will vary. Bigtimepennystocks.com and its staff are NOT licensed investment advisors or broker/dealers of any kind.Alerts are not a solicitation or recommendation to buy/sell/hold securities but merely investment ideas that should NEVER serve as the basis of your trading decisions. Bigtimepennystocks.com and its newsletter are for entertainment purposes only. This website and its reports are for general information purposes as we are engaged in the business of marketing and advertising companies for monetary compensation. Any investment decision should be discussed with a financial adviser before taking place. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.
Subscribe to our Free Newsletter
Copyright © 2023 BigTimePennyStocks.com - All Rights Reserved.